Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus HAIC for locally advanced HCC
NCT03869034Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2019
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Started Mar 2019; status: active, not recruiting.
02
Drugs
sintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03869034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03869034.